FLT3 and acute myeloid leukemia: The combination of gilteritinib and VEN (VenGilt) demonstrated efficacy in FLT3-ITD-mutated R/R-AML in a phase 1b multicenter, open label study (NCT03625505) of predominantly older (median age 63 years) patients [33].